Notice: This company has been marked as potentially delisted and may not be actively trading. Caladrius Biosciences (CLBS) News Today Add Compare Share Share Headlines Stock Analysis All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period HARBOUR BIOMED LAUNCHES NONA BIOSCIENCES' "IDEAS TO IND" PRECLINICAL SOLUTIONS BUSINESS TO ACCELERATE GLOBAL BIOTHERAPEUTIC INNOVATIONDecember 1, 2022 | finance.yahoo.comCaladrius Biosciences (NASDAQ:CLBS) Now Covered by Analysts at StockNews.comSeptember 20, 2022 | marketbeat.comCaladrius Biosciences, Inc.: Caladrius Biosciences and Cend Therapeutics Announce Closing of Merger and the Emergence of Lisata TherapeuticsSeptember 16, 2022 | finanznachrichten.deCaladrius Biosciences, Inc.: Caladrius Biosciences Announces Approval of Merger and Name Change to Lisata TherapeuticsSeptember 15, 2022 | finanznachrichten.deCaladrius Biosciences and Cend Therapeutics Announce Closing of Merger and the Emergence of Lisata TherapeuticsSeptember 15, 2022 | finance.yahoo.comCLBS Caladrius Biosciences, Inc.September 14, 2022 | seekingalpha.comCaladrius Biosciences Announces Approval of Merger and Name Change to Lisata TherapeuticsSeptember 14, 2022 | finance.yahoo.comHow to get the Protea Caladrius collection in Warframe: VeilbreakerSeptember 8, 2022 | msn.comCaladrius Biosciences Announces Participation in Upcoming Investor Conferences in September 2022September 8, 2022 | finance.yahoo.comCaladrius Biosciences’ Prospective Merger Partner, Cend Therapeutics, Announces Collaboration Agreement with Roche to Evaluate CEND-1 in Combination with Immunotherapy to Treat Pancreatic CancerAugust 10, 2022 | finance.yahoo.comCaladrius Biosciences, Inc. (CLBS) CEO David Mazzo on Q2 2022 Results - Earnings Call TranscriptAugust 5, 2022 | seekingalpha.comCaladrius Biosciences Reports Second Quarter 2022 Financial Results and Provides Business UpdateAugust 4, 2022 | finance.yahoo.comSHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates PING, CLBS, MANTAugust 4, 2022 | markets.businessinsider.comEarnings Outlook For Caladrius BiosciencesAugust 3, 2022 | msn.comCaladrius Biosciences Completes Enrollment in Phase 1b Study of CLBS201 for the Treatment of Diabetic Kidney DiseaseAugust 2, 2022 | finance.yahoo.comCaladrius Biosciences to Host Second Quarter 2022 Financial Results Conference Call on Thursday, August 4, 2022, at 4:30 p.m. Eastern TimeJuly 28, 2022 | finance.yahoo.comCaladrius Biosciences and Cend Therapeutics Announce Publication of Pancreatic Cancer Trial Data in The Lancet Gastroenterology and HepatologyJuly 6, 2022 | finance.yahoo.comCaladrius Biosciences Announces Merger Partner, Cend Therapeutics, has Treated First Patient in Phase 2b Trial of CEND-1 in Collaboration with Australasian Gastro-Intestinal Cancer Trials GroupJune 9, 2022 | finance.yahoo.comCaladrius Biosciences to Present at the BIO International Convention 2022June 8, 2022 | finance.yahoo.comCaladrius Biosciences and Cend Therapeutics Announce Poster Presentation at the 2022 American Society of Clinical Oncology Annual MeetingMay 26, 2022 | finance.yahoo.comCaladrius Biosciences Stops Enrollment In Mid-Stage Heart Disease StudyMay 24, 2022 | finance.yahoo.comCaladrius Biosciences Provides Update on Phase 2b FREEDOM Trial of XOWNA® in Coronary Microvascular DysfunctionMay 23, 2022 | finance.yahoo.comTrading was temporarily halted for "CLBS" at 04:05 PM with a stated reason of "News pending."May 23, 2022 | marketbeat.comCaladrius Biosciences Announces IDMC Recommendation to Advance CLBS201 Trial for the Treatment of Diabetic Kidney DiseaseMay 19, 2022 | finance.yahoo.comCaladrius Biosciences to Present at the H.C. Wainwright Global Investment ConferenceMay 18, 2022 | finance.yahoo.comCALADRIUS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Caladrius Biosciences, Inc. - CLBSMay 6, 2022 | benzinga.comCaladrius Biosciences, Inc. (CLBS) CEO David Mazzo on Q1 2022 Results - Earnings Call TranscriptMay 6, 2022 | seekingalpha.comCaladrius Biosciences Reports First Quarter 2022 Financial Results and Provides Business UpdateMay 5, 2022 | finance.yahoo.comCaladrius Biosciences Q1 2022 Earnings PreviewMay 4, 2022 | seekingalpha.comCALADRIUS BIOSCIENCES ALERT: Bragar Eagel & Squire, P.C. Investigates Merger of CLBS and Encourages Investors to Contact the FirmMay 2, 2022 | benzinga.comCaladrius Biosciences, IncApril 29, 2022 | stockhouse.comCaladrius Biosciences to Host First Quarter 2022 Financial Results Conference Call on Thursday, May 5, 2022, at 4:30 p.m. Eastern TimeApril 28, 2022 | finance.yahoo.comCLBS Stock Alert: Halper Sadeh LLP Is Investigating Whether the Merger of Caladrius Biosciences, Inc. Is Fair to ShareholdersApril 28, 2022 | apnews.comCaladrius Biosciences To Merge With Privately-Held Cend TherapeuticsApril 27, 2022 | finance.yahoo.comCaladrius Biosciences David J. Mazzo, Current Pres and CEO of Caladrius, Will Be CEO of Lisata >CLBSApril 27, 2022 | marketwatch.comCaladrius Biosciences to merge with Cend TherapeuticsApril 27, 2022 | seekingalpha.comTrading was temporarily halted for "CLBS" at 06:04 AM with a stated reason of "News pending."April 27, 2022 | marketbeat.comCaladrius Biosciences Treats First Patient In Phase 1b Trial Of CLBS201 For Treatment of Diabetic Kidney DiseaseApril 14, 2022 | benzinga.comCaladrius treats 1st patient in phase 1b trial of cell therapy CLBS201 for diabetic kidney diseaseApril 12, 2022 | seekingalpha.comCaladrius Biosciences Treats First Patient in the Phase 1b Trial of CLBS201 for the Treatment of Diabetic Kidney DiseaseApril 12, 2022 | finance.yahoo.comHC Wainwright Trims Caladrius Biosciences (NASDAQ:CLBS) Target Price to $6.00HC Wainwright dropped their price target on Caladrius Biosciences from $8.00 to $6.00 in a research report on Wednesday.March 23, 2022 | marketbeat.comRecap: Caladrius Biosciences Q4 EarningsMarch 23, 2022 | benzinga.comCaladrius Biosciences GAAP EPS of -$0.11March 22, 2022 | seekingalpha.comCaladrius Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business UpdateMarch 22, 2022 | finance.yahoo.comCaladrius Biosciences Q4 2021 Earnings PreviewMarch 21, 2022 | seekingalpha.comCaladrius Biosciences Earnings PreviewMarch 21, 2022 | benzinga.comCaladrius Biosciences to Host Fourth Quarter and Full Year 2021 Financial Results Conference Call on Tuesday, March 22, 2022, at 4:30 p.m. Eastern TimeMarch 15, 2022 | finance.yahoo.comCaladrius Biosciences Receives $2.3 Million of Non-Dilutive Capital Through New Jersey Technology Business Tax Certificate Transfer ProgramMarch 1, 2022 | sg.finance.yahoo.comCaladrius Biosciences Receives $2.3 Million of Non-Dilutive Capital Through New Jersey Technology Business Tax Certificate Transfer ProgramMarch 1, 2022 | finance.yahoo.comLongeveron Adds Seasoned Biotech Executive Todd Girolamo to Its Board of DirectorsFebruary 17, 2022 | finance.yahoo.com Get Caladrius Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for CLBS and its competitors with MarketBeat's FREE daily newsletter. Email Address Wall Street Icon: “You must get on the right side of this thing” (Ad)I created one of the first quantitative analysis-based stock picking systems long before "quants" became a thing on Wall Street… leading Forbes to call me "King of the Quants." I'm writing to you today because my system has recently uncovered a market phenomenon I haven't seen in 30 years. This market shakeup is going to be much more intense. CLBS Media Mentions By Week CLBS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CLBS News Sentiment▼0.000.60▲Average Medical News Sentiment CLBS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CLBS Articles This Week▼00▲CLBS Articles Average Week Get Caladrius Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for CLBS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies MNOV News DERM News CNTX News GUTS News ANRO News IMUX News PYXS News FONR News SKYE News IPSC News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CLBS) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the m...Porter & Company | SponsoredNvidia’s Bold Move: Tackling Tech’s $1 Trillion CrisisTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Caladrius Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Caladrius Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CLBS Stock Alerts